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such as immunoregulatory neuropeptides, play an important role. The
vasoactive intestinal peptide (VIP) and the corticotropin-releasing
factor (CRF)/urocortins (UCNs) family are neuropeptides expressed in
central and peripheral tissues, including immune cells, that modulate
the expression of inﬂammatory and extracellular matrix remodelling
mediators. VIP has previously shown a plethora of beneﬁcial effects,
both in inﬂammatory disorder animal models and in human OA, being
a potential therapeutic agent. Besides, it has shown that high VIP levels
are correlated with a decrease of the OA severity progress. In addition,
CRF and Urocortin1 (UCN1) are secreted to the OA joint microenvi-
ronment exerting an autocrine and paracrine immuno/inﬂammatory
regulation. Chondroitin sulfate (CS) is a Symptomatic Slow Action Drug
for Osteoarthritis (SYSADOA) described to improve the symptoms of OA
disease. The NIH-funded GAIT study demonstrated that CS is an effec-
tive drug in reducing OA patients’ synovitis. The aim of this study was to
compare the effect of CS vs. paracetamol on synovitis in OA patients,
and to evaluate their impact on VIP, CRF and UCN1 concentrations.
Methods: 71 OA patients with synovitis (synovial hyper-
trophy+effusion4mm) were treated with CS (Condrosan, CS Bio-
ActiveTM, Bioibérica S.A., Barcelona, Spain) (800mg/day) or para-
cetamol (4g/day) for 6 months. Patients were followed-up until month
9 to evaluate the CS carry-over effect. In each visit (0, 6 and 9 months)
synovitis was evaluated by sonography and plasma and synovial ﬂuid
were collected for the quantiﬁcation of VIP, CRF and UCN1 by EIA
(Enzyme Immunoassay). Once the clinical data have been collected, CS
treated patients were subdivided into two groups, as responding and
non-responding to treatment. A responding patient was deﬁned by
a sinovitis reduction at 6 months greater than 20% from basal value.
Time-course analysis study was performed by a Wilcoxon two-related
samples test. The comparation between responding and non-
responding patients was analyzed by a Mann-Whitney U test. P values
less than or equal to 0.05 were considered signiﬁcant.
Results: The analysis of the results obtained showed that CS but not
paracetamol reduces effectively the synovitis observed in OA patients.
The improvement remained after 3 months treatment cessation.
Synovial ﬂuid presents a progressive decrease neuropeptides levels
along the CS treatment, reaching signiﬁcancy VIP reduction at 9
months. This tendency is more pronounced when only the responding
patients are analyzed. In contrast no tendency was observed with the
paracetamol group, showing a lonely signiﬁcant decrease of UCN1 at 6
months. The neuropeptides levels in plasma did not show signiﬁcant
differences neither in the chondroitin treated patients nor in the
responding group. However, the paracetamol grup present a progres-
sive increment of CRF/UCN levels being signiﬁcant the UCN1 increase at
9 months. When comparing the basal levels of the neuropeptides
between responding and non-responding CS groups, we observed that
patients with high level of neuropeptides before CS treatment,
demonstrated a positive response to the treatment.
Conclusions: These results indicate that CS but not paracetamol
effectively reduces synovitis, even after leaving the CS treatment. This
improvement lead to a decreased VIP level in synovial ﬂuid, probably
because of a fall of the mediators that regulates its expression.
Neuropeptides levels could represent an important biomarker to
distinguish which patients are responder to CS, since high level of them
in synovial ﬂuid at the onset of treatment are correlated with a positive
response to CS treatment.Figure 1a. Cytokine Production from THP - 1 Macrophages After 24 Hours. 1b: Rela-
tionship between Chondroitin Sulphate (CS) Treatment Groups and IL-1b Production
by THP - 1 Macrophages at 24 Hours.389
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Purpose: Chondroitin Sulphate (CS), a natural glycosaminoglycan of the
cartilage extracellular matrix, has been shown to have some clinical
beneﬁt in symptomatic osteoarthritis (OA). While both OARSI and
EULAR have endorsed its use in certain types of OA, the exact mecha-
nism of action of CS is still unclear. Prior studies have shown that high
levels of CS could potentially cause precipitation of monosodium urate
(MSU) crystals leading to activation of the inﬂammasome. In vitro
studies have shown that CS has some anti-inﬂammatory effects on
chondrocytes and synoviocytes from OA patients. However, the effect of
CS on macrophages remains unclear and macrophages play a centralrole in OA pathogenesis. The purpose of our study was to evaluate the in
vitro effects of CS on cytokine production by macrophages.
Methods:We established an in vitro cell culture system using a human
monocytic cell line, THP-1(ATCC TIB-202). These cells were induced to
differentiate into mature macrophages using 12-O-tetradecanoyl-
phorbol-13-acetate (Enzo Life Sciences). To test the effects of CS on uric
acid (UA) solubility, we incubated sterile solutions of CS/UA is optimum
at various concentrations (CS 10-10000mg/ml & UA 10-500mg/ml). These
solutions were added to the macrophages in vitro to monitor for pro-
inﬂammatory effects; the solutions were also subjected to high speed
centrifugal ultra-ﬁltration to quantify, by HPLC, potential particulate
formation through analysis of the remaining soluble UA in the super-
natant. MSU crystals (Enzo Life Sciences) were used as a positive control
pro-inﬂammatory stimulus. Medium from the cultured cells was
removed at 6 and 24 hours and analyzed by immunoassay (R&D
Systems) for IL1b. These experiments were repeated with various
concentrations of a caspase-1 inhibitor (0.01mM-10mM, EMD Millipore)
to identify the component of IL1b production attributable to inﬂam-
masome activation. Finally, to test for anti-inﬂammatory effects of CS,
macrophages were pretreated with highly puriﬁed bovine CS (Bio-
ibérica, Barcelona, Spain) for 4 hours prior to the addition of MSU
crystals (200mg/ml) or Lipopolysaccharide (LPS) at 50mg/ml, which
served as a positive control. A range of doses of CS in the physiologic
range (10-200mg/ml) were tested. Culture medium was collected at 6
and 24 hours and IL1b levels were determined as above. Results were
analyzed using Graph Pad and linear trend analysis.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S206Results: The CS/UA solutions did not lead to inﬂammasome activation by
THP-1macrophages (datanot shown).MSU100mg/ml consistently resulted
in increased IL-1b production by macrophages; this IL-1 b productionwas
inhibitable by the caspase-1 inhibitor (at concentrations of 1 mMor greater)
conﬁrming activation of the inﬂammasome as the source of this cytokine
(data not shown). CS decreased IL-1 b production in both the LPS andMSU
treatment groups. While there was a trend toward a decreased inﬂam-
matory response at 6 hours, increasing doses of CS resulted in a signiﬁcant
dose-dependent inhibition of IL-1b production from macrophages by 24
hours (p-value¼0.0165 by linear trend analysis, see Figures 1a and 1b).
Conclusions: High concentrations of highly pure bovine CS do not
appear to facilitate formation of pro-inﬂammatory uric acid micro-
particulates or microcrystals formation. In contrast, CS can decrease IL-
1b production in a dose-dependent manner at physiologically achiev-
able concentrations of CS. The anti-inﬂammatory mechanism of CS
appears compatible with inhibition of inﬂammasome activation.
Additional research is required to further elucidate the speciﬁc means
by which this anti-inﬂammatory effect is mediated.
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Purpose: Chronic spinal pathology is related to degeneration of the inter-
vertebral disc. Although its exact etiology is unclear, early loss of highly
specialized cells in thenucleus pulposus (NP) has been associatedwithdisc
degeneration.AthoroughunderstandingofNPcelldevelopment is required
to design strategies to combat disk degeneration. The origin of cells in the
NP is under debate: NP cells originate from a different embryonal lineage
than articular chondrocytes and may comprise multiple functionally
distinct cells. In vitro standardized cell models for basic molecular studies,
are crucial for progress in intervertebral disc research. Herewe present the
ﬁrst clonal cell lines derived from the human nucleus pulposus.
Methods: Non-degenerated human disc material was obtained from
young adolescent donors as surgical surplus material. We immortalized
early passagemonolayer cultures by retroviral expression of the SV40LTAg
and hTERTgenes. Cell clones were obtained by a limiting dilution method
and screened for NP phenotype characteristics. Chondrogenic induction
was carried out using ITS, ascorbic acid and TGFb3 in monolayer, pellet
culture, alginate beads or aggrecan coated plates.
Results: Two distinct cellular subtypes were identiﬁed among clonally
expanded immortalized NP cell-pools (Figure 1A). These subtypes differ
in their ability to respond to chondrogenic differentiation conditionsFigure 1. NP cell clone characteristics. A) phase contrast images of representative
monolayer cultured NP subtypes. Bar indicates 20 microns. B) Gene expression of CA12,
FOXF1 and KRT19 in a monolayer differentiation assay. White bars: t¼0 ; black bars: t¼
7 days differentiation medium (DM). C) Representative responder and non-responder
clones were seeded on aggrecan coated plates in combination with control or DM. Fold
induction is shown, compared to non adhered cells for: SOX9, COL2A1, AGC1 and
COL1A1 is shown. Housekeeper is bActin.(responder versus non-responder) based on Collagen type II and SOX9
protein expression (data not shown). Responder clones, characterized
by awave-like cell organization, expressed high levels of established NP
markers CA12, FOXF1 and KRT19 (Figure 1B. right panel). Non-responder
clones, displayed a cobble-stone phenotype and displayed signiﬁcantly
less expression of NP cell markers (Figure 1B, left panel). Stimulation
with chondrogenic differentiation medium decreased expression of
CA12, FoxF1 and KRT19 (Figure 1B, black bars) and induced COMP
expression. To evaluate the effect of deﬁned culturing conditions on the
NP phenotype, we compared monolayer, alginate bead, pellet and
aggrecan coating cultures. Surprisingly, we found that aggrecan coating
induced the highest fold induction of COL2A1, SOX9 and AGC1 mRNA
expression in both NP subtypes (Figure 1C). In addition, aggrecan coating
uniquely induced CA12, FoxF1 and KRT19 expression, while differenti-
ation medium generally suppressed this effect. In contrast, alginate bead
or pellet culturing induced COL2A1 and SOX9 expression but failed to
induce AGC1, CA12, FoxF1 and KRT19 in NP cell clones.
Conclusions:We report the ﬁrst clonal cell lines representing the human
nucleus pulposus. Our phenotypic analyses show that the immortalized
cell clones correspond to their primary cell isolates and aggrecan coating
may provide an important niche factor in the context of NPdifferentiation
thanTGFb3 stimulation. Elucidating theNPcellularphenotype is expected
to result in development of tailored tissue engineering or regenerative
medicine approaches for NP-related spinal pathologies.
This research forms part of the Project P2.01 IDiDAS of the research
program of the BioMedical Materials institute, cofunded by the Dutch
Ministry of Economic Affairs, Agriculture and Innovation.
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Purpose: Osteoarthritis (OA) is a slow-developing, degenerative disease
characterised in part by structural deterioration of joint tissues. Visu-
alising and quantifying this change over short time periods would assist
early diagnosis and treatment strategies in clinic. Three dimensional
(3D) imaging methods such as micro-computed tomography allow for
a rapid and accurate evaluation of joint tissues in preclinical animal
models. The challenge, however, is to develop comprehensive methods
to sensitively discriminate between healthy and OA diseased joints. The
aim of this work is to demonstrate that measures of joint structural
alteration - namely, joint alignment, structural bone change, and
contact area - can sensitively discriminate between healthy and
diseased joints using a 3D imaging approach.
Methods: Eight 3-month old male Wistar rats underwent medial
meniscectomy/anterior cruciate ligament (ACL) desmotomy on one
knee (OP), where the non-operated contralateral joint served as
a control (NO). Animals were sacriﬁced 6 weeks post-operatively, the
joint space was ﬁlled with a contrast agent, and then scanned using
micro-computed tomography (mCT40, SCANCOMedical AG; 10 mmvoxel
size) [1]. Scans were processed and rotated to a common orientationFigure 1. The distance (l) and orientation (a, b, g) of the centre of mass of the femur
relative to the tibia. Results indicate increased joint instability with disease.
